Free Trial
NASDAQ:LXEO

Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Lexeo Therapeutics logo
$4.43 +0.05 (+1.14%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lexeo Therapeutics Stock (NASDAQ:LXEO)

Key Stats

Today's Range
$4.32
$4.50
50-Day Range
$2.63
$4.71
52-Week Range
$1.45
$19.50
Volume
193,219 shs
Average Volume
540,379 shs
Market Capitalization
$147.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Buy

Company Overview

Lexeo Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

LXEO MarketRank™: 

Lexeo Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 675th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexeo Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Lexeo Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lexeo Therapeutics are expected to grow in the coming year, from ($3.14) to ($2.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexeo Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexeo Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexeo Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lexeo Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.10% of the float of Lexeo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexeo Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Lexeo Therapeutics has recently increased by 26.46%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lexeo Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lexeo Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.10% of the float of Lexeo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexeo Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Lexeo Therapeutics has recently increased by 26.46%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lexeo Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,612.00 in company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of Lexeo Therapeutics is held by insiders.

  • Percentage Held by Institutions

    60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lexeo Therapeutics' insider trading history.
Receive LXEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LXEO Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

LXEO Stock Analysis - Frequently Asked Questions

Lexeo Therapeutics' stock was trading at $6.58 at the beginning of 2025. Since then, LXEO shares have decreased by 32.7% and is now trading at $4.43.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.19.

Lexeo Therapeutics (LXEO) raised $100 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at $11.00 per share.

Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
5/12/2025
Today
7/06/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LXEO
Previous Symbol
NASDAQ:LXEO
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.60
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+274.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$98.33 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$650 thousand
Price / Cash Flow
N/A
Book Value
$3.53 per share
Price / Book
1.25

Miscellaneous

Free Float
31,438,000
Market Cap
$147.08 million
Optionable
Not Optionable
Beta
1.32
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:LXEO) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners